Based on the three-dimensional structure of transferrin, the inventors have designed variant polypeptides (muteins) which have one or more Cysteine residues with a free thiol group (hereinafter referred to as "thiotransferrin"). The variant polypeptide may be conjugated through the sulphur atom of the Cysteine residue to a bioactive compound.
